A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression (NCT07300969)
A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.
Who can join: Review the eligibility criteria below.
Location: Draig Clinical Site — Bentonville, Arkansas
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (43 Sites)
Showing the first 25 of 43 sites.
- Draig Clinical Site — Bentonville, Arkansas
- Draig Clinical Site — Little Rock, Arkansas
- Draig Clinical Site — Oceanside, California
- Draig Clinical Site — San Diego, California
- Draig Clinical Site — Torrance, California
- Draig Clinical Site — Miami, Florida
- Draig Clinical Site — New Port Richey, Florida
- Draig Clinical Site — Orlando, Florida
- Draig Clinical Site — Atlanta, Georgia
- Draig Clinical Site — Decatur, Georgia
- Draig Clinical Site — Gaithersburg, Maryland
- Draig Clinical Site — Watertown, Massachusetts
- Draig Clinical Site — Flowood, Mississippi
- Draig Clinical Site — Las Vegas, Nevada
- Draig Clinical Site — Marlton, New Jersey
- Draig Clinical Site — New York, New York
- Draig Clinical Site — Media, Pennsylvania
- Draig Clinical Site — Austin, Texas
- Draig Clinical Site — Austin, Texas
- Draig Clinical Site — DeSoto, Texas
- Draig Clinical Site — Richardson, Texas
- Draig Clinical Site — Wichita Falls, Texas
- Draig Clinical Site — Bellevue, Washington
- Draig Clinical Site — Kazanlak,
- Draig Clinical Site — Plovdiv,
📞 Contact the Study Coordinator
Phone: +44(0)2920028450
Email: info@draigtherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Major Depressive Disorder (MDD)
- Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression — Arlington, Texas
- Neuroimaging Markers of Midlife Depression and Cognitive Behavioural Therapy (CBT) — Toronto, Ontario
- Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts — New York, New York
- Ketogenic Diet and Neuromodulation in Treatment Resistant Depression — Toronto, Ontario
- REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness — Greenwich, Connecticut
- Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder — Toronto, Ontario
Explore by condition: All Major Depressive Disorder (MDD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.